Improving outcomes in primary CNS lymphoma.
Best Pract Res Clin Haematol
; 31(3): 262-269, 2018 09.
Article
en En
| MEDLINE
| ID: mdl-30213395
Primary central nervous system lymphoma (PCNSL) is an aggressive disease with previously poor prognosis. The advent of high-dose methotrexate-based induction regimens as well as use of consolidation therapy has greatly improved this prognosis in recent decades, but durable remission still eludes half of patients. In this review, we summarize the progress made in the treatment of PCNSL as well as the challenges that remain, with a focus on defining optimal induction and consolidation regimens, including the promise of developing biotherapies. Future studies will help delineate the best combination of existing and novel treatment strategies, with the goal of expanding the cohort of patients achieving a cure.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Neoplasias del Sistema Nervioso Central
/
Linfoma
Límite:
Humans
Idioma:
En
Revista:
Best Pract Res Clin Haematol
Asunto de la revista:
HEMATOLOGIA
Año:
2018
Tipo del documento:
Article
Pais de publicación:
Países Bajos